Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859469 · ClinicalTrials.gov registry record · Phase 2
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
A Phase 2 study of Mesothelioma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00859469 is a Phase 2 study of Mesothelioma that has completed, run by Columbia University. The registered enrollment target is 29 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00859469, a Phase 2 study of Mesothelioma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859469
The ClinicalTrials.gov registry entry for NCT00859469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (85% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00859469 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00859469 about?
NCT00859469 is a clinical study titled "Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma". In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
What is the current status of trial NCT00859469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2004-04. Estimated completion is 2013-03.
What conditions does trial NCT00859469 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT00859469?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00859469?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00859469 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.